New Preorder Patent Owner Rights in Ex Parte Reexamination — Patents: Post-Grant Podcast
At the Intersection of Biotech and AI with Janice Vatland
Protecting Your Products and Brand Online
IP Goes Pop! S7 Ep 1- We’re #1! Intellectual Property Firsts
Michele Moresco on the Transformational Potential of Photonics
AI in Biotech: What Does it Mean for Life Sciences Innovation?
The Briefing: 2025 IP Resolutions Start With a Review of IP Assets (Featured)
The Briefing: A Very Patented Christmas – The Quirkiest Inventions for the Holiday Season (Featured)
(Podcast) The Briefing: A Very Patented Christmas – The Quirkiest Inventions for the Holiday Season (Featured)
Practical IP Lessons From the Field: Field Trials, Trade Secrets, and the Hydrogen Horizon - Energy Law Insights
Practical IP Lessons From the Field Part Two: Navigating IP Risk in Oil & Gas - Energy Law Insights
Practical IP Lessons From the Field Part One: Protecting Innovation in Oil & Gas - Energy Law Insights
AI Today in 5: October 27, 2025, The Trusting Your Eyes Edition
It Only Took 13 Years: The Federal Circuit's First Derivation Proceeding Decision — Patents: Post-Grant Podcast
PODCAST: Williams Mullen's Trending Now: An IP Podcast - Who Owns AI Innovation? IP in the Age of Artificial Intelligence
Money-Saving Licensing Tips for Startups
Understanding the Impact of IPR Estoppel and PTAB Discretionary Denials — Patents: Post-Grant Podcast
5 Key Takeaways | Making Sense of §102 Public Use and On Sale Bars to Patentability
Unexpected Paths to IP Law with Dan Young and Colin White
Navigating PTAB’s New Approach to IPR and PGR Discretionary Denial - Patents: Post-Grant Podcast
Key Takeaways: In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Supreme Court reversed the Federal Circuit and held that a generic drug manufacturer’s FDA-compliant skinny label, combined with...more
On June 4, 2026, the United States Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. In its decision, the Supreme Court reversed the Federal Circuit, and held that Amarin’s complaint...more
The Senate passed the reconciliation 2.0 package, which funds ICE and CBP and includes no healthcare provisions. The bill now moves to the House, though Republican leadership cancelled Friday votes, postponing further action...more
Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they...more
Etanercept Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
The Supreme Court held that inducement of patent infringement requires active, affirmative statements or actions encouraging infringement, not merely statements that could be read as encouraging infringement....more
Denosumab Challenged Claim Types in Litigation: Claims are counted in each litigation, so claims from the same patent challenged in multiple litigations are counted more than once. Within each litigation a claim is counted...more
Pegfilgrastim Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Three recent patent rulings underscore courts’ increasing scrutiny of damages and equitable relief theories by emphasizing real‑world economic and evidentiary support over formalistic assumptions:...more
Artificial intelligence tools — from consumer-facing platforms to enterprise-deployed systems— are now deeply embedded in scientific, engineering, and product development workflows. The rise of generative AI and machine...more
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 - Introduction - Yesterday, the Supreme Court held in a unanimous 9-0 decision that induced patent infringement requires active steps to encourage...more
A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s cardiovascular-use patents — a decisive...more
Eligibility wins at the Federal Circuit are scarce enough that any decision finding a claim to survive § 101 is worth a read. Constellation Designs, LLC v. LG Electronics Inc. is worth two reads, because the panel managed to...more
Adalimumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
Rituximab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
The United States Patent and Trademark Office (USPTO) has introduced a new “Pre-Docketing Notice” pilot program aimed at improving transparency and efficiency in the patent examination process. Under this program, applicants...more
Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as...more
Insulin Glargine Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the same patent challenged in multiple...more
The Supreme Court issued its decision today in Hikma Pharmaceuticals v. Amarin Pharma, addressing what it takes to successfully plead a claim for indirect patent infringement...more
Personalized medicine continues to reshape life sciences innovation, but it also introduces unique challenges in today’s evolving legal landscape....more
A single word appeared 241 times in Enviro Tech’s patent specification. The word was “about.” Not once was it defined. In May 2026, the Federal Circuit invalidated all 27 asserted claims. Complete annihilation. Not because...more
Determining the amount of disclosure sufficient to satisfy the written description and enablement requirements of 35 U.S.C. § 112(a) can be difficult, especially in the fields of biotechnology, pharmaceuticals, and other...more
As AI continues to advance at pace, securing patent protection for AI‑related inventions has become increasingly important, particularly for maintaining competitive advantage and attracting investment. But as with many...more
KEY TAKEAWAYS - • CPG companies often create patentable and protectable IP in packaging, formulation, manufacturing, sustainability, and brand-design work, not just in formal R&D. • Lost value usually comes from timing...more